European Congress of Rheumatology

Brian LaMoreaux, MD, discusses data from an analysis of the MIRROR trial examining the impact of pegloticase plus methotrexate on patient-reported outcomes and quality of life measures among patients with uncontrolled gout.

Between 2000 and 2019, age-standardized incidence rates of autoimmune diseases increased by 4%.

An analysis of 100 week data from the KEEPsAKE 1 and 2 trials presented at EULAR 2023 offers insight into the long-term effects of risankizumab use in people with psoriatic arthritis.

Adverse events were significantly more frequently reported by pregnant patients when compared with non-pregnant patients. However, no differences were observed when comparing pregnant patients with autoimmune disease and healthy controls.

An analysis of patient-reported outcomes data from the MIRROR trial offers insight into the effects of pegloticase plus methotrexate on quality of life and various disease activity indices.

New data from EULAR 2023 offers a comparison of the levels of vascular inflammation among patients with psoriatic arthritis relative to healthy controls.

The results of the study provide a proof of concept for upadacitinib treatment in patients with systemic lupus erythematosus.

Patients treated with upadacitinib maintained greater improvements in SLE disease activity, lupus flares, and time to first flare when compared with the placebo cohort.

Data indicate dazodalibep has the potential to address unmet therapeutic needs for patients with Sjögren’s syndrome.

An analysis of patient data from Sweden and Norway detail the impact of achieving remission with methotrexate or TNF inhibitors on risk of acute coronary syndrome in patients with rheumatoid arthritis.

An analysis of NHANES data from 2011-2018 presented at EULAR 2023 offers an overview of the disproportionate growth in gout burden for Asian Americans relative to their White counterparts.

Data from the BE VITAL OLE study, which included patients from the BE COMPLETE and BE OPTIMAL studies, suggests the benefits of bimekizumab in patients with psoriatic arthritis with inadequate response or intolerance to TNF inhibitors were sustained for up to 52 weeis.

The phase 3 research being presented at the EULAR 2022 conference evaluated the efficacy and safety of upadacitinib in patients with active non-radiographic axial spondyloarthritis.

Dr. Eliseo Pascual's presentation at EULAR 2022 serves as a reminder to consider gender bias during the diagnosis, treatment, and management of rheumatic diseases.

Research presented at EULAR aims to enhance communication with a conversation aid so patients can address challenges they encounter as a result of rheumatic and musculoskeletal disease with a rheumatologist.

Bristol Myers Squibb shares positive phase 2 results evaluating deucravacitinib in patients with moderate-to-severe systemic lupus erythematosus.

Dr. Richard Furie explains the link between systemic lupus erthematosus and COVID-19.

Dr. Vibeke Strand discusses the relationship between COVID-19 and psoriatic arthritis.

Dr. Vibeke Strand discusses how better treatment of psoriatic arthritis could yield better treatments for NASH.

A clinical rheumatologist breaks down how the combination therapy can be used to treat uncontrolled gout.

The drug is well-tolerated in methotrexate inadequate response patients with rheumatoid arthritis.

Patients who cannot tolerate cDMARDs may experience additional value from tocilizumab compared to adalimumab.

Dr. Philip Mease explains the next steps for testing the efficacy and safety of upadacitinib for patients with psoriatic arthritis.

Dr. Dennis McGonagle said guslekumab is also being tested in patients with inflammatory bowel disease.

Dr. Philip Mease discusses some of the treatments currently being tested for effectiveness against COVID-19.

Rheumatoid arthritis patients with probably major depressive disorder or generalized anxiety disorder were more likely to suffer from worse fatigue and pain.

Dr. Philip Mease explains the relationship between rheumatoid arthritis and psoriatic arthritis.

More patients maintain therapeutic response when treated concomitantly with methotrexate and pegloticase when compared to those who use pegloticase alone.

A team investigated data from trials of tofacitinib, adalimumab, and placebo.

Study drug also recently showed promise in treating psoriatic arthritis.